|
gptkbp:instanceOf
|
gptkb:chemical_compound
antidepressant
serotonin–norepinephrine reuptake inhibitor
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:Japan
gptkb:United_States
|
|
gptkbp:approvedForFibromyalgiaInUS
|
2009
|
|
gptkbp:ATCCode
|
N06AX17
|
|
gptkbp:bioavailability
|
85%
|
|
gptkbp:brand
|
gptkb:Savella
gptkb:Ixel
Toledomin
|
|
gptkbp:CASNumber
|
92623-85-3
|
|
gptkbp:contraindication
|
uncontrolled narrow-angle glaucoma
concurrent MAOI use
|
|
gptkbp:developedBy
|
gptkb:Pierre_Fabre_Médicament
|
|
gptkbp:drugClass
|
SNRI
|
|
gptkbp:eliminationHalfLife
|
8 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1980s
|
|
gptkbp:hasInChIKey
|
gptkb:QFFGVLORLPOAEC-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C15H22N2O
|
|
gptkbp:hasSMILES
|
CCN(CC)C(C)(C1=CC=CC=C1)C(C)NC
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
milnacipran
|
|
gptkbp:IUPACName
|
(±)-1-diethylamino-1-phenyl-2-(methylamino)propan-1-ol
|
|
gptkbp:KEGGID
|
D08209
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibition
serotonin reuptake inhibition
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
246.35 g/mol
|
|
gptkbp:patent
|
1982
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1427
4047
4191
DB01418
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
headache
hypertension
insomnia
palpitations
dry mouth
increased sweating
hot flush
|
|
gptkbp:UNII
|
WK2XYI10QM
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
fibromyalgia
|
|
gptkbp:bfsParent
|
gptkb:Serotonin-norepinephrine_reuptake_inhibitors
gptkb:Venlafaxine
gptkb:serotonin-norepinephrine_reuptake_inhibitors
gptkb:SNRIs
|
|
gptkbp:bfsLayer
|
7
|